cyclin L1 Antibody (Q-1): sc-81843

Cyclin L1 Antibody (Q-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects cyclin L1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-cyclin L1 antibody (Q-1) is available as a non-conjugated format. Cyclin L1 is a crucial regulatory protein that plays a significant role in cell cycle, particularly in mRNA splicing regulation. Cyclin L1 is predominantly located in the nucleus and is essential for proper pre-mRNA processing, which is vital for synthesizing proteins that drive cellular functions. Cyclin L1′s importance in mRNA splicing is underscored by interactions with POLR2A, CDC2L, and SFRS2, which are involved in transcription and splicing machinery. Cyclin L1 dysregulation has been implicated in various cancers, including head and neck squamous cell carcinomas, where cyclin L1 can be overexpressed and function as a proto-oncogene. Cyclin L1′s ability to modulate mRNA splicing not only influences gene expression but also impacts cellular responses to external signals, making cyclin L1 a critical component in maintaining cellular homeostasis and function.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

cyclin L1 Antibody (Q-1) References:

1. Cyclin L is an RS domain protein involved in pre-mRNA splicing.  |  Dickinson, LA., et al. 2002. J Biol Chem. 277: 25465-73. PMID: 11980906
2. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer.  |  Redon, R., et al. 2002. Cancer Res. 62: 6211-7. PMID: 12414649
3. Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain: phosphorylation by DYRK1A and colocalization with splicing factors.  |  de Graaf, K., et al. 2004. J Biol Chem. 279: 4612-24. PMID: 14623875
4. Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells.  |  Yang, L., et al. 2004. J Biol Chem. 279: 11639-48. PMID: 14684736
5. Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.  |  Naaz, A., et al. 2004. FASEB J. 18: 1925-7. PMID: 15469964
6. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC).  |  Sticht, C., et al. 2005. Br J Cancer. 92: 770-4. PMID: 15700036
7. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.  |  Chen, HH., et al. 2006. Mol Cell Biol. 26: 2736-45. PMID: 16537916
8. Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma.  |  Muller, D., et al. 2006. Br J Cancer. 94: 1041-4. PMID: 16598186
9. Characterization of cyclin L1 as an immobile component of the splicing factor compartment.  |  Herrmann, A., et al. 2007. FASEB J. 21: 3142-52. PMID: 17494991
10. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection.  |  Loyer, P., et al. 2008. J Biol Chem. 283: 7721-32. PMID: 18216018
11. CDK11 requires a critical activator SAP30BP to regulate pre-mRNA splicing.  |  Wang, C., et al. 2023. EMBO J. 42: e114051. PMID: 38059508
12. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway.  |  Zhang, Y., et al. 2024. Aging (Albany NY). 16: 11208-11223. PMID: 39024509